Clinical Trials Logo

Bone Metastasis clinical trials

View clinical trials related to Bone Metastasis.

Filter by:

NCT ID: NCT01765907 Completed - Bone Metastasis Clinical Trials

Antalgic Treatment of Painful Bone Metastases by US-guided High Intensity Focused Ultrasound (HIFU)

Start date: December 2012
Phase: Phase 1
Study type: Interventional

Antalgic treatment of painful bone metastases by US-guided High Intensity Focused Ultrasound (HIFU).

NCT ID: NCT01309048 Completed - Bone Metastasis Clinical Trials

Magnetic Resonance-Guided High Intensity Focused Ultrasound for Palliation of Painful Skeletal Metastases

Start date: January 2011
Phase: Phase 1/Phase 2
Study type: Interventional

This study is to confirm the safety and technical of MRI guided High Intensity Focused Ultrasound (HIFU) for Palliation for Pain of Skeletal Metastases. MRI guided high intensity focused ultrasound uses ultrasound to heat and thermally ablate tissue. The MRI system identifies the ultrasound path and monitors heat rise in the tissue. The goal of the study is to show treatment safety and effectiveness. MR-guided HIFU will be performed in patients who pass inclusion/exclusion criteria.

NCT ID: NCT01062503 Completed - Clinical trials for Metastatic Prostate Cancer

Duration of Suppression of Bone Turnover Following Treatment With Zoledronic Acid in Men With Metastatic CRPC

SubDueP
Start date: January 2010
Phase: N/A
Study type: Observational

Bone is the most common site of metastases in prostate cancer and bone complications cause substantial morbidity to this population. Phase III studies have shown that zoledronic acid is effective in decreasing the morbidity associated with bone metastases. Zoledronic acid (ZA) is generally well tolerated but may have side effects such as hypocalcemia, renal impairment and osteonecrosis of the jaw. Administration of ZA as infrequently as once yearly is sufficient to prevent osteopenia or osteoporosis. The optimal treatment interval is unknown, but the drug is often empirically administered every 3-4 weeks. The cost of such treatment is high, and the risk of exposing patients (especially those at low risk) to potential serious side effects with uncertain benefit warrants investigation. This study will determine the duration of suppression of bone turnover in prostate cancer patients with bone metastases following a single infusion of Zoledronic Acid and its effect on quality of life.

NCT ID: NCT00610272 Completed - Pain Clinical Trials

Optimization of Radiotherapy in Treatment of Painful Bone Metastasis

bone mets
Start date: January 2008
Phase: Phase 3
Study type: Interventional

Bone metastasis is one of the most frequent end complications of the cancer. Radiation therapy is the mainstay of treatment in this disease. Single fraction radiotherapy in both single and multiple bone metastasis is widely used, but optimization of the single dose fractionation is needed. Two different regimens of radiotherapy dose fractionation will be investigated in both single and multiple bone metastasis and endpoints will include pain relief as well as toxicity and quality of life.

NCT ID: NCT00334139 Completed - Breast Cancer Clinical Trials

Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer

Start date: May 2006
Phase: Phase 4
Study type: Interventional

Bisphosphonates have been used extensively in the treatment and the prevention of skeletal complications associated with bone metastases in patients with breast cancer and prostate cancer. The purpose of this study is to assess the effect of zoledronic acid patients with prostate cancer or breast cancer and bone metastasis.